tremelimumab-actl
View Patient InformationA human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab-actl binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.
| Synonym: | anti-CTLA4 human monoclonal antibody CP-675,206 ticilimumab tremelimumab |
|---|---|
| US brand name: | Imjudo |
| Code name: | CP-675 CP-675,206 CP-675206 |
| Chemical structure: | immunoglobulin G2, anti-(human CTLA-4 (antigen)) (human monoclonal CP-675206 clone 11.2.1 heavy chain) disulfide with human monoclonal CP-675206 clone 11.2.1 light chain, dimer |